FDA加速批准泽布替尼用于复发或难治性滤泡性淋巴瘤
正文 · 中文译文
FDA加速批准泽布替尼用于复发或难治性滤泡性淋巴瘤 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2024年3月7日,美国食品药品监督管理局(FDA)加速批准泽布替尼(Brukinsa,百济神州美国公司)联合奥妥珠单抗用于既往接受过至少两线系统性治疗的复发或难治性滤泡性淋巴瘤(FL)成人患者。 Brukinsa的完整处方信息将在此处发布。 该方案在BGB-3111-212研究(ROSEWOOD;NCT03332017)中进行了评估,该研究是一项开放标签、多中心、随机试验,入组了217例既往接受过至少2线系统性治疗的复发或难治性FL成人患者。患者按2:1随机接受泽布替尼160 mg口服每日两次直至疾病进展或出现不可接受的毒性联合奥妥珠单抗(ZO)治疗,或单独接受奥妥珠单抗治疗。既往治疗线数中位数为3(范围2-11)。 疗效基于独立审查委员会确定的总体缓解率(ORR)和缓解持续时间(DOR)。ZO组的ORR为69%(95% CI:61,76),obinutuzumab组为46%(95% CI:34,58)(双侧p值,0.0012)。中位随访时间为19.0个月,ZO组的中位DOR未达到(95% CI:25.3个月,NE),接受obinutuzumab单药治疗的患者为14.0个月(95% CI:9.2,25.1)。ZO组18个月时的估计DOR率为69%(95% CI:58,78)。 在zanubrutinib的各项临床试验中,最常见的不良反应(≥30%),包括实验室异常,为中性粒细胞计数降低(51%)和血小板计数降低(41%)、上呼吸道感染(38%)、出血(32%)和肌肉骨骼疼痛(31%)。接受ZO治疗的FL患者中有35%发生了严重不良反应。 zanubrutinib的推荐剂量为160 mg口服每日两次或320 mg口服每日一次,直至疾病进展或出现不可接受的毒性。 本审评使用了Assessment Aid,这是申请人自愿提交以促进FDA审评的材料。 本申请获得了快速通道认定和孤儿药认定。FDA加速程序的描述见《行业指南:严重疾病药物和生物制品的加速程序》。 医疗保健专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 对于研究性肿瘤产品的单患者IND(新药临床研究申请)相关协助,医疗保健专业人员可致电OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X(原Twitter)上关注肿瘤卓越中心 @FDAOncology。 内容更新日期: 03/07/2024 受监管产品 药品 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Full prescribing information for Brukinsa will be posted here. The regimen was evaluated in Study BGB-3111-212 (ROSEWOOD; NCT03332017), an open-label, multicenter, randomized trial that enrolled 217 adult patients with relapsed or refractory FL after at least 2 prior systemic treatments. Patients were randomized (2:1) to receive either zanubrutinib 160 mg orally twice daily until disease progression or unacceptable toxicity plus obinutuzumab (ZO), or obinutuzumab alone. The median number of prior lines of therapy was 3 (range 2-11). Efficacy was based on overall response rate (ORR) and duration of response (DOR) determined by an independent review committee. ORR was 69% (95% CI: 61, 76) in the ZO arm and 46% (95% CI: 34, 58) in the obinutuzumab arm (two-sided p-value, 0.0012). With a median follow-up of 19.0 months, the median DOR was not reached in the ZO arm (95% CI: 25.3 months, NE) and was 14.0 months (95% CI: 9.2, 25.1) for those patients receiving obinutuzumab monotherapy. The estimated DOR rate at 18 months was 69% (95% CI: 58, 78) in the ZO arm. Across clinical trials of zanubrutinib, the most common adverse reactions (≥30%), including laboratory abnormalities, were decreased neutrophil counts (51%) and platelet counts (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%). Serious adverse reactions occurred in 35% of patients with FL who received ZO. The recommended zanubrutinib dosage is 160 mg taken orally twice daily or 320 mg taken orally once daily until disease progression or unacceptable toxicity. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted fast track designation and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology. Content current as of: 03/07/2024 Regulated Product(s) Drugs Oncology